Mirum Pharmaceuticals Inc.

11/15/2021 | Press release | Distributed by Public on 11/15/2021 11:38

Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome